Halozyme Therapeutics HALO Finished goods
Finished goods at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:InventoryFinishedGoodsNetOfReserves.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's finished goods.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's finished goods?
- Halozyme Therapeutics (HALO) reported finished goods of $113.37M in Q1 2026.
- How has Halozyme Therapeutics's finished goods changed year-over-year?
- Halozyme Therapeutics's finished goods decreased by 20.9% year-over-year, from $143.24M to $113.37M.
- What is the long-term trend for Halozyme Therapeutics's finished goods?
- Over 5 years (2020 to 2025), Halozyme Therapeutics's finished goods has grown at a 46.8% compound annual growth rate (CAGR), from $21.2M to $144.45M.
- What does finished goods mean?
- Completed products ready for sale, valued at the lower of cost or net realizable value.